US Pharma MarketingFDA
The White House is reviewing a new FDA-biopharma user fee deal that includes Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA:…
The White House is examining a deal recently reached by the FDA and the biopharma industry that sets the prescription drug user fees that the sector will pay the agency from 2028 through 2032, sources ...
Source: Endpoints News